Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries
Overview
Affiliations
Background: Prostanoid synthesis via the action of cyclooxygenase-2 (COX-2) is a component of the inflammatory response. Prostacyclin, a product of COX-2 in vascular endothelium, has important physiological roles, such as increasing blood flow to injured tissues, reducing leukocyte adherence, and inhibiting platelet aggregation. We examined the possibility that selective COX-2 inhibition could suppress the protective effects of prostacyclin, resulting in an alteration of the hemostatic balance and vascular tone.
Methods And Results: Circumflex coronary artery thrombosis was induced in dogs by vascular electrolytic injury. Orally administered celecoxib (COX-2 inhibition) or high-dose aspirin (HDA) (COX-1 and COX-2 inhibition) did not alter time to occlusive thrombus formation compared with controls (celecoxib 77.7+/-7.2 minutes, HDA 72.0+/-18.5 minutes, control 93.0+/-21.8 minutes). Oral HDA with an endothelial recovery period (HDA-ER) (COX-1 inhibition) produced a significant increase in time to vessel occlusion (257.0+/-41.6 minutes). The observed increase in time to occlusion was abolished when celecoxib was administered to animals dosed with HDA-ER (80.7+/-20.6 minutes). The vasomotor effect of endothelium-derived prostacyclin was examined by monitoring coronary flow during intracoronary administration of arachidonic acid or acetylcholine. In celecoxib-treated animals, vasodilation in response to arachidonic acid was reduced significantly compared with controls.
Conclusions: The results indicate important physiological roles for COX-2-derived prostacyclin and raise concerns regarding an increased risk of acute vascular events in patients receiving COX-2 inhibitors. The risk may be increased in individuals with underlying inflammatory disorders, including coronary artery disease.
Guevara-Balcazar G, Ramirez-Sanchez I, Mera-Jimenez E, Rubio-Gayosso I, Aguilar-Najera M, Castillo-Hernandez M Korean J Physiol Pharmacol. 2017; 21(4):407-413.
PMID: 28706454 PMC: 5507779. DOI: 10.4196/kjpp.2017.21.4.407.
Transmission pathways and mediators as the basis for clinical pharmacology of pain.
Kirkpatrick D, McEntire D, Smith T, Dueck N, Kerfeld M, Hambsch Z Expert Rev Clin Pharmacol. 2016; 9(10):1363-1387.
PMID: 27322358 PMC: 5215101. DOI: 10.1080/17512433.2016.1204231.
Coon D, Chen L, Boctor E, Prince J, Bojovic B J Reconstr Microsurg. 2015; 32(4):251-5.
PMID: 26645155 PMC: 4991775. DOI: 10.1055/s-0035-1568158.
Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation.
Ruzov M, Rimon G, Pikovsky O, Stepensky D Br J Clin Pharmacol. 2015; 81(2):316-26.
PMID: 26456703 PMC: 4833168. DOI: 10.1111/bcp.12801.
Rubio-Ruiz M, Perez-Torres I, Diaz-Diaz E, Pavon N, Guarner-Lans V Acta Pharmacol Sin. 2014; 35(11):1364-74.
PMID: 25263337 PMC: 4220071. DOI: 10.1038/aps.2014.67.